Equities research analysts at StockNews.com assumed coverage on shares of CEL-SCI (NYSE:CVM – Get Rating) in a report released on Thursday. The brokerage set a “hold” rating on the stock.
CEL-SCI Price Performance
CEL-SCI Company Profile
CEL-SCI Corp. is a biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers.
See Also
- Get a free copy of the StockNews.com research report on CEL-SCI (CVM)
- 5 Best Bank ETFs to Buy Now
- How to Invest in Telehealth and Telemedicine Stocks
- Target’s Guidance Looms Over The MarketÂ
- Want Clean Energy? Siemens May Be Pointing To A Breakout
- Up Over 2,600% in 5 Years, Wall Street Still Calls Celsius a Buy
Receive News & Ratings for CEL-SCI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CEL-SCI and related companies with MarketBeat.com's FREE daily email newsletter.
